281 related articles for article (PubMed ID: 17391318)
1. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review.
Gisbert JP; González-Lama Y; Maté J
Am J Gastroenterol; 2007 Jul; 102(7):1518-27. PubMed ID: 17391318
[TBL] [Abstract][Full Text] [Related]
2. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients.
Gisbert JP; Luna M; González-Lama Y; Pousa ID; Velasco M; Moreno-Otero R; Maté J
Inflamm Bowel Dis; 2007 Sep; 13(9):1106-14. PubMed ID: 17455203
[TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
van Asseldonk DP; Seinen ML; de Boer NK; van Bodegraven AA; Mulder CJ
J Crohns Colitis; 2012 Feb; 6(1):95-101. PubMed ID: 22261533
[TBL] [Abstract][Full Text] [Related]
4. Why measure thiopurine methyltransferase activity? Direct administration of 6-thioguanine might be the alternative for 6-mercaptopurine or azathioprine.
de Jong D; Mulder CJ; van Sorge AA
Gut; 2001 Dec; 49(6):874. PubMed ID: 11758505
[No Abstract] [Full Text] [Related]
5. More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing.
Broekman MMTJ; Coenen MJH; van Marrewijk CJ; Wanten GJA; Wong DR; Verbeek ALM; Klungel OH; Hooymans PM; Guchelaar HJ; Scheffer H; Derijks LJJ; de Jong DJ;
Inflamm Bowel Dis; 2017 Oct; 23(10):1873-1881. PubMed ID: 28644183
[TBL] [Abstract][Full Text] [Related]
6. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
Derijks LJ; de Jong DJ; Gilissen LP; Engels LG; Hooymans PM; Jansen JB; Mulder CJ
Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):63-7. PubMed ID: 12544696
[TBL] [Abstract][Full Text] [Related]
7. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.
Ansari A; Elliott T; Baburajan B; Mayhead P; O'Donohue J; Chocair P; Sanderson J; Duley J
Aliment Pharmacol Ther; 2008 Sep; 28(6):734-41. PubMed ID: 19145729
[TBL] [Abstract][Full Text] [Related]
9. Azathioprine and 6-Mercaptopurine-induced Liver Injury: Clinical Features and Outcomes.
Björnsson ES; Gu J; Kleiner DE; Chalasani N; Hayashi PH; Hoofnagle JH;
J Clin Gastroenterol; 2017 Jan; 51(1):63-69. PubMed ID: 27648552
[TBL] [Abstract][Full Text] [Related]
10. Peliosis hepatis induced by 6-thioguanine administration.
Larrey D; Fréneaux E; Berson A; Babany G; Degott C; Valla D; Pessayre D; Benhamou JP
Gut; 1988 Sep; 29(9):1265-9. PubMed ID: 3198003
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease.
Rulyak SJ; Saunders MD; Lee SD
J Clin Gastroenterol; 2003 Mar; 36(3):234-7. PubMed ID: 12590235
[TBL] [Abstract][Full Text] [Related]
12. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.
de Boer NK; Reinisch W; Teml A; van Bodegraven AA; Schwab M; Lukas M; Ochsenkühn T; Petritsch W; Knoflach P; Almer S; van der Merwe SW; Herrlinger KR; Seiderer J; Vogelsang H; Mulder CJ;
Digestion; 2006; 73(1):25-31. PubMed ID: 16493198
[TBL] [Abstract][Full Text] [Related]
13. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
Leong RW; Gearry RB; Sparrow MP
Expert Opin Drug Saf; 2008 Sep; 7(5):607-16. PubMed ID: 18759713
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of tolerance to mercaptopurine in patients with inflammatory bowel disease and gastrointestinal intolerance to azathioprine.
Bastida G; Alvarez-Sotomayor D; Aguas M; Iborra M; Del Hoyo J; Béjar-Serrano S; Garrido-Marín A; Valero-Pérez E; Nos P
Gastroenterol Hepatol; 2024 May; 47(5):473-480. PubMed ID: 38072359
[TBL] [Abstract][Full Text] [Related]
16. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent?
Derijks LJ; Gilissen LP; de Boer NK; Mulder CJ
J Hepatol; 2006 Apr; 44(4):821-2. PubMed ID: 16487623
[No Abstract] [Full Text] [Related]
17. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients.
Shaye OA; Yadegari M; Abreu MT; Poordad F; Simon K; Martin P; Papadakis KA; Ippoliti A; Vasiliauskas E; Tran TT
Am J Gastroenterol; 2007 Nov; 102(11):2488-94. PubMed ID: 17764490
[TBL] [Abstract][Full Text] [Related]
18. The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease: a retrospective observational study.
Gensmyr-Singer H; Werner M; Karling P
Therap Adv Gastroenterol; 2024; 17():17562848241228064. PubMed ID: 38384282
[TBL] [Abstract][Full Text] [Related]
19. Review article: thiopurines in inflammatory bowel disease.
Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
[TBL] [Abstract][Full Text] [Related]
20. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease.
Gupta P; Gokhale R; Kirschner BS
J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):450-4. PubMed ID: 11698762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
